IDEAS home Printed from https://ideas.repec.org/p/ess/wpaper/id3058.html
   My bibliography  Save this paper

Drug Companies Should Be Held More Accountable for Their Human Rights Responsibilities

Author

Listed:
  • PLoS Medicine

Abstract

The PLoS Medicine Editors argue that drug companies should be held much more accountable for their human rights responsibilities

Suggested Citation

  • PLoS Medicine, 2010. "Drug Companies Should Be Held More Accountable for Their Human Rights Responsibilities," Working Papers id:3058, eSocialSciences.
    • Handle: RePEc:ess:wpaper:id:3058
    Note: Policy Matters
    as

    Download full text from publisher

    File URL: http://www.esocialsciences.org/Download/repecDownload.aspx?fname=Document120102010320.6809198.pdf&fcategory=Articles&AId=3058&fref=repec
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Sofia Gruskin & Zyde Raad, 2010. "Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment," PLOS Medicine, Public Library of Science, vol. 7(9), pages 1-3, September.
    2. Geralyn S Ritter, 2010. "Are Drug Companies Living Up to Their Human Rights Responsibilities? The Merck Perspective," PLOS Medicine, Public Library of Science, vol. 7(9), pages 1-2, September.
    3. Paul Hunt & Rajat Khosla, 2010. "Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former United Nations Special Rapporteur (2002-2008)," PLOS Medicine, Public Library of Science, vol. 7(9), pages 1-3, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sabine Vogler, 2019. "Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies," Empirica, Springer;Austrian Institute for Economic Research;Austrian Economic Association, vol. 46(3), pages 443-469, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Margaret Oppenheimer & Helen LaVan & William Martin, 2015. "A Framework for Understanding Ethical and Efficiency Issues in Pharmaceutical Intellectual Property Litigation," Journal of Business Ethics, Springer, vol. 132(3), pages 505-524, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ess:wpaper:id:3058. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Padma Prakash (email available below). General contact details of provider: http://www.esocialsciences.org .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.